41 results about "Glomerular sclerosis" patented technology

Disclosed are single nucleotide polymorphisms (SNIps) associated with breast cancer, lung cancer, prostate cancer, non-insulin dependent diabetes, end stage renal disease due to non-insulin dependent diabetes, hypertension, end stage renal disease F due to hypertension, myocardial infarction, colon cancer, hypertension, atherosclerotic peripheral vascular disease due to hypertension, cerebrovascular accident due to hypertension, cataracts due to hypertension, cardiomyopathy with hypertension, myocardial infarction due to hypertension, non-insulin dependent diabetes mellitus, atherosclerotic peripheral vascular disease due to non-insulin dependent diabetes mellitus, cerebrovascular accident due to non-insulin dependent diabetes mellitus, ischemic cardiomyopathy, ischemic cardiomyopathy with non-insulin dependent diabetes mellitus, myocardial infarction due to non-insulin dependent diabetes mellitus, atrial fibrillations without valvular disease, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease. cholecystectomy, degenerative joint disease, end stage renal disease and frequent de-clots, end stage renal disease due to focal segmental glomerular sclerosis, end stage renal disease due to insulin dependent diabetes mellitus, or seizure disorder. Also disclosed are methods for using SNPs to determine susceptibility to these diseases; nucleotide sequences containing SNPs; kits for determining the presence of SNPs; and methods of treatment or prophylaxis based on the presence of SNPs.

The invention relates a pharmaceutical composition comprising a combination of:(i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, such as Alzheimer's, glaucoma and stroke, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

The invention discloses a method for building a diabetic nephropathy microinflammation mice model. The method comprises the steps of choosing db / db mice, inducing a microinflammation state through casein subcutaneous, and carrying out histopathological analysis on clinical biochemical indexes and tissues. The method has the characteristics of being simple to operate, economic and practical, high in modeling success rate and the like; the disease features of human diabetic nephropathy can be simulated; and the method has the characteristics of microinflammation, glomerular mesangial matrix proliferation, glomerular sclerosis and the like. Building of the method benefits for looking into the damage mechanism of the diabetic nephropathy; and occurrence and development of the diabetic nephropathy are well prevented.

The invention relates to applications of niclosamide ethanolamine salt and a medicinal composition of the niclosamide ethanolamine salt. After the niclosamide ethanolamine salt and the medicinal composition of the niclosamide ethanolamine salt are applied, an uncoupling effect can be achieved on the kidney tissue mitochondria, the excretion of proteinuria of mice with kidney diseases can be reduced, the glomerular sclerosis and renal tubular injuries can be improved, the level of serum creatinine can be reduced, and therefore, the niclosamide ethanolamine salt and medicinal composition of theniclosamide ethanolamine salt have a certain protection effect for the kidney diseases, and can be used for preventing and treating the kidney diseases.

The invention discloses a yang warming and blood activating traditional Chinese compound preparation for preventing and treating chronic kidney diseases and application thereof. Raw materials of the traditional Chinese compound preparation comprise the components: 15-30g of cistanche, 15-30g of herba epimedii, 10-15g of peach kernel, 10-15g of flowers carthami and 10-15g of moutan bark. In use, the traditional Chinese compound preparation is decocted with water. The invention further provides the application of the traditional Chinese compound preparation for preventing and treating chronic kidney diseases, namely, the traditional Chinese compound preparation can be used for researching pathogenesis of aristolochzc acid nephropathy and use for interferring a rat model with IgAN glomerular sclerosis. According to the yang warming and blood activating traditional Chinese compound preparation for preventing and treating chronic kidney diseases provided by the invention, aiming at the deficiencies in treatment of chronic kidney diseases at present, a novel treating and researching method for chronic kidney diseases is provided, so that the current research status for curative effect in treatment of chronic kidney diseases can be better improved.

The invention discloses a process for preparing low-molecular-weight fucoidan, wherein the low-molecular-weight fucoidan is prepared through the process steps of hydrochloric acid degradation, desalination, ion exchange column elution and the like. Proved by pharmacological activity experiments, the low-molecular-weight fucoidan prepared by adopting the method disclosed by the invention is capable of obviously improving renal function, reducing proteinuria, slowing glomerular sclerosis and playing a role of protecting kidney. Proved by animal experiments, the effect of the low-molecular-weight fucoidan is obviously better than that of fucoidan with the same dose, so that the low-molecular-weight fucoidan disclosed by the invention can be used for preparing drugs for treating diabetic nephropathy or can be directly used as a drug for treating the diabetic nephropathy.

This invention provides a compound of formula (I):or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.

Crystalline forms of the sulfate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the sulfate salt are characterized by a variety of properties and physical measurements. As well, methods of producing the sulfate salts, and using such salts to inhibit excessive tyrosine kinase activity in subjects to treat a number of diseases including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer (e.g., leukemia such as acute lymphocytic leukemia), glomerulosclerosis fibrotic diseases and inflammation, and general treatment of cell-proliferative diseases, are also discussed.

The invention describes and claims the use of vasopeptidase inhibitors of formula (I) for the treatment of nephropathy in diabetic or non-diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistance or of metabolic diseases associated with advanced glycation end-products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and / or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.

The invention discloses application of reagent of markers for detecting focal segmental glomerulosclerosis (FSGS) to preparation of a kit for diagnosing and predicating focal segmental glomerulosclerosis, the focal segmental glomerulosclerosis markers are one or more of miR-17, miR-451, miR-106a and miR-19B, By means of the markers for diagnosing and predicating focal segmental glomerulosclerosis, new blood markers are provided for clinical diagnosis of focal segmental glomerulosclerosis, peripheral blood testing can be directly conducted, and the markers have the advantages of being good in specificity and high in sensitivity, have good clinical diagnosis value and lay a foundation for implementation of hematology diagnosis of FSGS.

The invention discloses an application of an IgAN glomerular sclerosis rat model. The establishing method of the IgAN glomerular sclerosis rat model comprises the following steps of: step 1, selecting a rat, lavaging the rat with bovine serum albumin acidulated aqueous solution on the next day after the rat is raised for 1 week, injecting staphylococcus aureus B-type enterotoxin solution from the vein of the penis of the rat, and injecting complete a Freund's adjuvant from the enterocoelia of the rat during the period from the second week to the fourth week; and step 2, nephrectomizing the rat for two times at the fifth week and the sixth week, and cutting five sixths of the whole kidney at two times. The application of the rat model comprises the application in pathology research of an IgAN glomerular sclerosis process. According to the IgAN glomerular sclerosis rat model disclosed by the invention, the manufacturing time for the IgAN glomerular sclerosis rat model is shortened, the generation and the development of nephridial tissue fibrillation are enhanced, and the scientific research work of IgA nephropathy medical science can be better served.

The invention discloses a use of capparis spinosa in preparing drugs for treating kidney diseases, in particular to an application in preparing drugs for treating focal segmental glomerulus sclerosis. The invention explains the action mechanism of the medicine through the therapeutic effects of capparis spinosa on the focal segmental glomerulus sclerosis of rat models and the initial screening of gene chips, and shows remarkable curative effect on kidney diseases through the clinical experiment of the medicine prepared by capparis spinosa, in which no side effects as bone marrow suppression, liver damage and so on are found, thus being proved to have a broad application prospect.

The invention relates a pharmaceutical composition comprising a combination of:(i) the AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, such as Alzheimer's, glaucoma and stroke, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.

The invention relates to applications of Kindlin-2 protein as a target point in preparing medicines for treating nephritis. The research result shows that after the Kindlin-2 gene is specifically knocked out, the content of urine protein of mice is obviously increased, while the content of plasma protein is obviously reduced, meanwhile, the structure of glomeruli of the kidney is severely damaged, and the obvious glomerular sclerosis and interstitial fibrosis exist. The experimental result of the research shows that Kindlin-2 protein can be taken as a novel target point for preparing the medicines for treating nephritis.

The present invention provides a method of improving the phenomenon of the glomerular sclerosis and mononuclear leukocyte infiltration around renal tissues, and increasing the renal function by administering the probiotic bacterium of a Parabacteroides goldsteinii to a subject in need to inhibit the occurrence of chronic kidney disease. The Parabacteroides goldsteinii can also effectively modulate the gene expression level of MCP-1, IL-1β, COL3A, COL6A1, ACAA2, PPAR-γ, CPT1, and PGC-1α in kidney tissues to reduce kidney inflammation and renal fibrosis and enhance the mitochondria activity of kidney cells. Therefore, the Parabacteroides goldsteinii of the present invention can be utilized in pharmaceutical compositions for inhibiting or treating chronic kidney diseases.

The invention belongs to the field of molecular biological marker diagnosis and prognosis evaluation and relates to an application of a urea Tenascin-C: creatinine in preparing preparation for diagnosing and prognosis evaluating idiopathic IgA nephropathy. The urea Tenascin-C: creatinine (uTNC / Cr) as a marker can be used for diagnosing the severity of illness of the idiopathic IgA nephropathy andprognosis evaluation. By detecting the level of the urea Tenascin-C: creatinine, a result shows that the uTNC / Cr level of a patent with idiopathic IgA nephropathy is higher than that of a normal person, and the urea TNC is ejected along with urea after lesion expression of segment glomerular sclerosis, crescent in kidney tissues and the like. Meanwhile, the uTNC / Cr level can reflect the expressionquantity of TNC of glomerulus, reflect the severity of lesion of IgA nephropathy and can assist prognosis evaluation of the IgA nephropathy indirectly. The invention provides a preparation which is time-saving, high in sensitivity and accuracy, low in cost and efficient in diagnosing and prognosis evaluating idiopathic IgA nephropathy compared with prior art and a kit for the application.

The invention provides cordyceps cicadae composite medicine for treating diabetic nephropathy and a preparation method thereof and belongs to the field of traditional Chinese medicine. The cordyceps cicadae composite medicine for treating diabetic nephropathy is prepared from the following raw materials in parts by weight: 18 to 22 parts of cordyceps cicadae, 14 to 16 parts of radix rehmanniae, 14to 16 parts of common yam rhizome, 8 to 12 parts of fructus lycii, 8 to 12 parts of fructus corni, 8 to 12 parts of achyranthes root, 14 to 16 parts of fried radix astragali seu hedysari, 8 to 12 parts of radix salvia miltiorrhizae, 8 to 12 parts of poria with hostwood and 5 to 7 parts of chamomile flower. The composite medicine has scientific and rigovous compatibility and complete assistant andguide and has the effects of tonifying qi and yin, promoting blood circulation to remove blood stasis, nourishing liver and kidney and can achieve an effect of treating both symptoms and root causeson the diabetic nephropathy. Research data show that aqueous extract of the cordyceps cicadae composite medicine can effectively inhibit aldose reductase and reduce expression of TGF-beta1 protein, alpha-SMA protein and FN protein of renal tubular epithelial cells; thus, damage to the glomerulus cells is reduced, glomerular sclerosis is relieved, tubular interstitial fibrosis is inhibited, pathological change of the kidney is lightened, illness state development can be inhibited and converted, and a better treating and protecting effect on the diabetic nephropathy is achieved.

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.

Provided is a pharmaceutical composition that contains a 1, 2-dithiolthionederivative, and is effective to prevent and treat a disease caused by overactivity of a liver X receptor alpha (LXR alpha) or a sterol response element binding protein (SREBP-1). Specifically, the pharmaceutical composition includes 1, 2-dithiolthione derivatives such as 4-methyl-5-(2-pyrazinyl)-1, 2-dithiol-3-thione, 3-methyl-1, 2-dithiol-3-thione, or 5-(6-methoxypyrazinyl)-4-methyl-1, 2-dithiol-3-thione. The pharmaceutical composition is effective for preventing and treating hypertension caused by renin, aldosteronism, adrenoleukodystrophy, glomerulosclerosis, proteinuria, nephropathy, liver steatosis, hypertriglyceridemia or hyperreninemia.

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

The invention relates to the field of medicine and pharmacology, in particular to medicine for treating focal segmental glomerulus sclerosis. The medicine is an oral preparation prepared by combining astaxanthin and fresh ginger with the conventional traditional Chinese medicine theory and pharmacology study result and utilizing the modern process measures, and is preferably a capsule or a tablet. Through the verification by pharmacodynamic experiments, the medicine has the ideal treatment effect on glomerulus sclerosis; in addition, the medicine provided by the invention has high safety; the tolerance and the compliance of a patient are high; and the treatment cost is low.